BRAF and melanoma: Melanoma cell responsiveness to BRAF kinase inhibitors (BRAFi) may vary depending on the level of expression of the BRAF gene/BRAF mRNA level [10], and approximately 15% of melanomas are characterized by intrinsic resistance mechanisms [11].